ARS Pharma Q1 FY26 net loss widens to $60.6 million; revenue rises to $22.7 million

ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc.

SPRY

0.00
  • ARS Pharmaceuticals posted Q1 2026 revenue of USD 22.7 million, including USD 17.5 million in U.S. net product revenue from neffy.
  • Net loss widened to USD 60.6 million, or USD 0.61 per share.
  • SG&A expenses climbed to USD 72.2 million; R&D expenses were USD 4.3 million.
  • Cash, cash equivalents, and short-term investments totaled USD 201 million as of March 31, 2026, with management saying this is sufficient to fund operations through cash-flow break-even.
  • CVS Caremark formulary proposal is in final-stage review with a target July 1, 2026 effective date; sales force expansion to 148 representatives was completed and Phase 2b CSU interim population is fully enrolled with Q4 2026 data expected.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ARS Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-225055), on May 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.